Publication: Retinal Ven Tıkanıklığında Yeni Gelişmeler ve Güncel Tedavi Seçenekleri
Abstract
Retina ven tıkanıklığı (RVO) en sık rastlanan retinal vasküleranomalilerden biridir. BRVO’ lu hastalarda görme kaybının ensık nedeni olan maküla ödemi tedavisi zamanla değişim göster-miştir. Lazer fotokoagülasyonun görme kaybı riskini azalttığı vegörme keskinliğini arttırdığı gösterilmiştir, ancak lazer ile görseliyileşme genellikle yavaş ve yetersizdir. İntravitreal ajanlardaki,özellikle anti-vasküler endotelyal büyüme faktörlerinin (VEGF)son yıllardaki gelişimi görmenin iyileştirilmesine önemli kat-kılar sağlamıştır. Randomize klinik çalışmalarda, anti-VEGFajanların (ranibizumab, bevacizumab ve afl ibercept), lazer teda-visine kıyasla daha iyi sonuçlar sağladığı bildirilmiştir. Bu der-lemede, tedavi seçeneklerini değerlendiren randomize kontrollüçalışmaların sonuçları özetlenmektedir.
Retinal vein occlusion (RVO) is one of the most common occur- ring retinal vascular abnormalities. The management of macular edema that is the most common cause of visual loss in patients with BRVO has changed considerably over time. The laser photo- coagulation has been shown to decrease the risk of visual loss and improve visual acuity (VA), however, visual recovery with the laser is usually slow and incomplete. It has made important contribu- tions in improving the development of recent intravitreal agents, especially in anti-vascular endothelial growth factors (VEGF). Randomized clinical trials have reported optimal results with an- ti-VEGF agents (ranibizumab, bevacizumab, and afl ibercept) com- pared to laser therapy. This review article summarizes evidence from randomized controlled trials evaluating treatment options.
Retinal vein occlusion (RVO) is one of the most common occur- ring retinal vascular abnormalities. The management of macular edema that is the most common cause of visual loss in patients with BRVO has changed considerably over time. The laser photo- coagulation has been shown to decrease the risk of visual loss and improve visual acuity (VA), however, visual recovery with the laser is usually slow and incomplete. It has made important contribu- tions in improving the development of recent intravitreal agents, especially in anti-vascular endothelial growth factors (VEGF). Randomized clinical trials have reported optimal results with an- ti-VEGF agents (ranibizumab, bevacizumab, and afl ibercept) com- pared to laser therapy. This review article summarizes evidence from randomized controlled trials evaluating treatment options.